Celldex Therapeutics, Inc.
CLDXNext catalyst
CDX-301
Breast Cancer
Get an email about CLDX's next catalysts
Track Celldex Therapeutics (CLDX) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 3 more upcoming events in our data (earnings, Phase 2 readout).See the timeline
5 upcoming, 2 past
CLDX Earnings Report
Date estimated from past reporting pattern, not yet confirmed by the company | EPS Est: $-1.02 | FQ end Sep/2026 | Call: tbd
CDX-301 Phase 2 Est. Readout (CBCV)
Estimated primary completion for CDX-301 trial (NCT03804944) in Breast Cancer. Topline data typically follows completion by weeks to months.
SourcePhase 3 — barzolvolimab
For chronic spontaneous urticaria (CSU). Celldex announced positive Phase 3 results for barzolvolimab in chronic spontaneous urticaria, with both EMBARQ-CSU1 and EMBARQ-CSU2 trials meeting primary and key secondary endpoints. The company plans to submit a BLA to the FDA in 2027.
Phase III CSU trials hit endpoints with durable responses
SourceAnti-CD40 Agonist Monoclonal Antibody CDX-1140 Phase 2 Est. Readout
Estimated primary completion for Anti-CD40 Agonist Monoclonal Antibody CDX-1140 trial (NCT05231122) in Ovarian Clear Cell Adenocarcinoma. Topline data typically follows completion by weeks to months.
SourceHuman CMV pp65-LAMP mRNA-pulsed autologous DCs Phase 2 Est. Readout (DERIVe)
Estimated primary completion for Human CMV pp65-LAMP mRNA-pulsed autologous DCs trial (NCT03688178) in Glioblastoma. Topline data typically follows completion by weeks to months.
SourceMarket Overview
Stock performance and key metrics
barzolvolimab
Prurigo Nodularis
KLH
Glioblastoma
Rindopepimut (CDX-110) with GM-CSF
Glioblastoma
CDX-011
Metastatic gpNMB Over-expressing Triple Negative Breast Cancer
CDX-110 with GM-CSF
Malignant Glioma
NeoAg-mBRAF
Melanoma
FLT3 Ligand Therapy (CDX-301)
Non-small Cell Lung Cancer (NSCLC)
Human CMV pp65-LAMP mRNA-pulsed autologous DCs
Glioblastoma
DEC-205/NY-ESO-1 Fusion Protein CDX-1401
Fallopian Tube Carcinoma
Varlilumab
B Cell Lymphoma
CDX-301
Breast Cancer
rhuFlt3L/CDX-301
Low-Grade B-cell Lymphoma
Flt3L
Non-Hodgkin's Lymphoma
Anti-CD40 Agonist Monoclonal Antibody CDX-1140
Ovarian Clear Cell Adenocarcinoma
poly-ICLC
Advanced Malignancies
CDX-1127
Melanoma
Montanide ISA-51
Melanoma
CDX-1401
Advanced Malignancies
polyICLC
Melanoma
Resiquimod
Advanced Malignancies
Poly ICLC
Fallopian Tube Carcinoma
CDX-1140
Melanoma
Unpulsed DCs
Glioblastoma
6MHP
Melanoma
CDX-1401 in combination with Resiquimod and/or Poly-ICLC
Advanced Malignancies
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
barzolvolimab | Phase 3 | Prurigo Nodularis | - | - |
KLH | Phase 3 | Glioblastoma | - | - |
Rindopepimut (CDX-110) with GM-CSF | Phase 3 | Glioblastoma | - | - |
CDX-011 | Phase 2 | Metastatic gpNMB Over-expressing Triple Negative Breast Cancer | - | - |
CDX-110 with GM-CSF | Phase 2 | Malignant Glioma | - | - |
NeoAg-mBRAF | Phase 2 | Melanoma | - | - |
FLT3 Ligand Therapy (CDX-301) | Phase 2 | Non-small Cell Lung Cancer (NSCLC) | - | - |
Human CMV pp65-LAMP mRNA-pulsed autologous DCs | Phase 2 | Glioblastoma | - | - |
DEC-205/NY-ESO-1 Fusion Protein CDX-1401 | Phase 2 | Fallopian Tube Carcinoma | - | - |
Varlilumab | Phase 2 | B Cell Lymphoma | - | - |
CDX-301 | Phase 2 | Breast Cancer | - | - |
rhuFlt3L/CDX-301 | Phase 2 | Low-Grade B-cell Lymphoma | - | - |
Flt3L | Phase 2 | Non-Hodgkin's Lymphoma | - | - |
Anti-CD40 Agonist Monoclonal Antibody CDX-1140 | Phase 2 | Ovarian Clear Cell Adenocarcinoma | - | - |
poly-ICLC | Phase 2 | Advanced Malignancies | - | - |
CDX-1127 | Phase 2 | Melanoma | - | - |
Montanide ISA-51 | Phase 2 | Melanoma | - | - |
CDX-1401 | Phase 2 | Advanced Malignancies | - | - |
polyICLC | Phase 2 | Melanoma | - | - |
Resiquimod | Phase 2 | Advanced Malignancies | - | - |
Poly ICLC | Phase 2 | Fallopian Tube Carcinoma | - | - |
CDX-1140 | Phase 2 | Melanoma | - | - |
Unpulsed DCs | Phase 2 | Glioblastoma | - | - |
6MHP | Phase 2 | Melanoma | - | - |
CDX-1401 in combination with Resiquimod and/or Poly-ICLC | Phase 2 | Advanced Malignancies | - | - |
Frequently asked questions
What is in Celldex Therapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 25 drug candidates in Celldex Therapeutics, Inc.'s (CLDX) pipeline across Phase 3, Phase 2. Its lead program is barzolvolimab (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Celldex Therapeutics, Inc.'s next FDA catalyst?→
Celldex Therapeutics, Inc.'s (CLDX) next tracked catalyst is a Phase 2 readout expected December 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track CLDX biotech catalysts?→
Add CLDX to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Celldex Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.